Citenazone

General description The MystiCq &#174: microRNA qPCR Assay Primer is an integral part of the MystiCq microRNA qPCR Assay System. It has been designed to target specific microRNAs with the MystiCq Universal PCR primer and the MystiCq &#174:

NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.An antiproliferative agent, and inhibitor of DNA-PK.

mAb (C04/3D7): Mouse anti Human PCNA Antibody (FITC): Flow Cytometry: IF/ICC

mAb (C04/3D7): Mouse anti Human PCNA Antibody (FITC): Flow Cytometry: IF/ICC

mAb (C04/3D7): Mouse anti Human PCNA Antibody (FITC): Flow Cytometry: IF/ICC

mAb (C04/3D7): Mouse anti Human PCNA Antibody (FITC): Flow Cytometry: IF/ICC

InformationR-10015 R-10015 is a potent, selective inhibitor of LIM domain kinase (LIMK) with IC50 of 38 nM for human LIMK1. R-10015 binds to the ATP-binding pocket and acts as a broad-spectrum antiviral compound for HIV infection.TargetshLIMK1

InformationR-10015 R-10015 is a potent, selective inhibitor of LIM domain kinase (LIMK) with IC50 of 38 nM for human LIMK1. R-10015 binds to the ATP-binding pocket and acts as a broad-spectrum antiviral compound for HIV infection.TargetshLIMK1

InformationR-10015 R-10015 is a potent, selective inhibitor of LIM domain kinase (LIMK) with IC50 of 38 nM for human LIMK1. R-10015 binds to the ATP-binding pocket and acts as a broad-spectrum antiviral compound for HIV infection.TargetshLIMK1

InformationR-10015 R-10015 is a potent, selective inhibitor of LIM domain kinase (LIMK) with IC50 of 38 nM for human LIMK1. R-10015 binds to the ATP-binding pocket and acts as a broad-spectrum antiviral compound for HIV infection.TargetshLIMK1

InformationR-10015 R-10015 is a potent, selective inhibitor of LIM domain kinase (LIMK) with IC50 of 38 nM for human LIMK1. R-10015 binds to the ATP-binding pocket and acts as a broad-spectrum antiviral compound for HIV infection.TargetshLIMK1

InformationSRI-29329 is a potent, specific inhibitor of CDC-like kinase (CLK) that targets CLK1, 2 and 4, respectively.